{"nct_id":"NCT06500702","title":"A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2024-12-19","start_date_type":"ACTUAL","primary_completion_date":"2026-12-23","primary_completion_date_type":"ESTIMATED","completion_date":"2028-02-16","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["SNY"]}